Endoscopic, Reconstructive & Cosmetic Surgery Foundation Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-11-2024
- Paid Up Capital ₹ 0.50 M
as on 15-11-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit -2.74%
(FY 2023)
- Ebitda -2.74%
(FY 2023)
- Net Worth -4.79%
(FY 2023)
- Total Assets -0.72%
(FY 2023)
About Endoscopic, Reconstructive & Cosmetic Surgery Foundation
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rajinder Verma and Navneet Magon serve as directors at the Company.
- CIN/LLPIN
U85300CH2018NPL041955
- Company No.
041955
- Company Classification
Private Not For Profit Company
- Incorporation Date
12 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Endoscopic, Reconstructive & Cosmetic Surgery Foundation?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navneet Magon  | Managing Director | 12-Apr-2018 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajinder Verma | Director | 14-Apr-2018 | Current |
Financial Performance of Endoscopic, Reconstructive & Cosmetic Surgery Foundation.
Endoscopic, Reconstructive & Cosmetic Surgery Foundation, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 2.74% decrease in profit. The company's net worth dipped by a decrease of 4.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Endoscopic, Reconstructive & Cosmetic Surgery Foundation?
In 2023, Endoscopic, Reconstructive & Cosmetic Surgery Foundation had a promoter holding of 98.00% and a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Endoscopic, Reconstructive & Cosmetic Surgery Foundation?
Unlock and access historical data on people associated with Endoscopic, Reconstructive & Cosmetic Surgery Foundation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Endoscopic, Reconstructive & Cosmetic Surgery Foundation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Endoscopic, Reconstructive & Cosmetic Surgery Foundation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
